Dendreon is a biopharmaceutical company targeting cancer through the discovery, development, commercialization, and manufacturing of novel therapeutics. Its product Provenge is an autologous cellular immunotherapy for the treatment of asymptomatic or minimally symptomatic metastatic, castrate-resistant (hormone-refractory) prostate cancer.
Missing: Dendreon's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Dendreon's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing Dendreon
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Dendreon is included in 3 Expert Collections, including Cancer.
Pharmaceutical and biotechnology companies with cancer therapy drug candidates.
Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).
Dendreon has filed 27 patents.
Clusters of differentiation, Immunology, Immune system, Monoclonal antibodies, Transcription factors
Clusters of differentiation, Immunology, Immune system, Monoclonal antibodies, Transcription factors
Latest Dendreon News
Feb 2, 2023
News Provided By Share This Article Immuno-oncology Market Immuno-oncology is the study and development of treatments that take advantage of the body’s immune system to fight cancer. BURLINGAME, CALIFORNIA, UNITED STATES, February 2, 2023 / EINPresswire.com / -- Immuno-oncology Market Size Projections : The global Immuno-oncology drugs market is estimated to be valued at US$ 17,394.2 million in 2022 and is expected to exhibit a CAGR of 16.8% during the forecast period (2023-2030). The market study on Immuno-oncology Market examines the topic in respect to a number of industry elements, including market size, status, trends, and prediction. Additionally, the report offers a brief synopsis of rival companies as well as particular growth opportunities with significant market drivers. The research includes a thorough evaluation of the Immuno-oncology market, split by companies, regions, types, and applications. Immuno-oncology medications target the immune system, one of the body's inherent defences, to combat cancer. Cancer is a collection of disorders brought on by the unchecked development and division of aberrant cells. Oncology medications are therapeutics used to treat cancer. Various types of medicines, such as chemotherapeutic agents, targeted treatments, immunotherapies, and hormone therapies, are included in the category of immuno-oncology pharmaceuticals. The negative effects of cancer medications can also be treated with a variety of medications. In immunotherapy, a specific component of the patient's immune system is used to combat disease. This is accomplished either by boosting the patient's own immune system to fight cancer cells more vigorously or by administering immune system components such synthetic immune system proteins. Edition : 2023 What's New In 2023 For Immuno-oncology Market : ⁍ Scope For 2023. ⁍ Market presence in multiple geographies that is strong/active/niche/trivial. ⁍ Top players in the market. ⁍ Research framework (structure of the report). ⁍ Personalized online interactive peer-to-peer updates. Scope of Immuno-oncology For 2023: Immuno-oncology Market research assesses the rate of growth and market value based on market dynamics and growth generating variables. Complete understanding is based on the most recent industry news, prospects, and trends. The research includes a thorough market analysis and vendor landscape, as well as a SWOT analysis of the top vendors. Major companies in Immuno-oncology Market are: AbbVie Inc., AstraZeneca, Bristol-Myers Squibb Company, Dendreon Pharmaceuticals LLC., F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Novartis AG, Pfizer Inc., Sanofi, Ferring B.V., Enzo Biochem Inc., Celldex Therapeutics, Atara Biotherapeutics, Inc., Apexigen, BioNTech SE, Blueprint Medicines Corporation, Regeneron Pharmaceuticals Inc., CytomX Therapeutics, Inc., Agenus Inc., Betta Pharmaceuticals Co., Ltd., CStone Pharmaceuticals, Amgen Inc., MediMergent, LLC, Gilead Sciences, Inc., and ONKO-INNATE → Additionally, this report discusses the major factors influencing market growth as well as the possibilities, risks, and challenges that the industry as a whole and key competitors in particular face. It also looks at important new trends and how they might affect both present and future growth. → The in-depth review of the global Immuno-oncology market's new developments, controversial trends, market pilots already in place, challenges, norms, and technical domain. This report also splits the market by region: Americas, United States, Canada, Mexico, Brazil, APAC, China, Japan, Korea, Southeast Asia, India, Australia, Europe, Germany, France, UK, Italy, Russia, Spain, Middle East and Africa, Egypt, South Africa, Israel, Turkey, GCC Countries Buy Now with Exclusive Offer https://www.coherentmarketinsights.com/insight/buy-now/1271 Global Immuno-oncology Market 2022 Key Insights: – Examine the current state of the Immuno-oncology market and its future prospects in relation to production, Immuno-oncology pricing structure, consumption, and previous experience. – The research identifies the many segments and sub-segments that make up the structure of the Immuno-oncology market. – Market historical information from 2016 to 2022 and forecast through 2030. Market breakdown information by company, products, end-users, and key countries. – Analysis of the Immuno-oncology market's growth patterns, prospects for the future, and contribution to the entire keyword market. – Report on the Global Immuno-oncology Market 2023 examines competitive developments such as contracts, the introduction of new products, and Immuno-oncology Market acquisition. – To characterize sales volume, Immuno-oncology revenue, growth potential, drivers, SWOT analysis, and Immuno-oncology development plans in the upcoming years, the research report targets the major international Immuno-oncology players. Highlights of the Global Immuno-oncology report: ‣ A complete backdrop analysis, which includes an assessment of the Immuno-oncology Market ‣ An objective assessment of the trajectory of the market ‣ Market segmentation up to the second or third level ‣ Reporting and evaluation of recent industry developments ‣ Important changes in market dynamics ‣ Emerging niche segments and regional markets ‣ Historical, current, and projected size of the market from the standpoint of both value and volume ‣ Market shares and strategies of key players ‣ Recommendations to companies for strengthening their foothold in the market The research was compiled based on the synthesis, analysis, and interpretation of data gathered from numerous sources on the parent market. Furthermore, the economic conditions and other economic indicators and determinants have been studied in order to analyse their respective impact on the Immuno-oncology Market, as well as the current impact, in order to generate strategic and informed forecasts regarding the market scenarios. This is mostly due to the developing world's unmet potential in terms of product pricing and income creation. Buy Now with Exclusive Offer https://www.coherentmarketinsights.com/insight/buy-now/1271 About us: Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients. Mr. Shah +1 2067016702
Dendreon Frequently Asked Questions (FAQ)
When was Dendreon founded?
Dendreon was founded in 1992.
Where is Dendreon's headquarters?
Dendreon's headquarters is located at 1208 Eastlake Avenue East, Seattle.
What is Dendreon's latest funding round?
Dendreon's latest funding round is Acquired.
How much did Dendreon raise?
Dendreon raised a total of $48.5M.
Who are the investors of Dendreon?
Investors of Dendreon include Sanpower, Bausch Health, Morgan Stanley, LRG Capital Group, Mazama Capital Management and 9 more.
Who are Dendreon's competitors?
Competitors of Dendreon include Akron Biotechnology, Keryx Biopharmaceuticals, CureTech, Biosceptre International, Threshold Pharmaceuticals, Tau Therapeutics, Jennerex Biotherapeutics, REGiMMUNE, Regado Biosciences, Stemgent and 25 more.
Compare Dendreon to Competitors
Scientists at Epeius Biotechnologies have developed a targeted delivery system (TDS) that can transport genes or other therapeutic agents directly to diseased areas in the body. This pathotropic, or disease-seeking, technology has enabled the company to develop Rexin-G, a tumor-targeted, injectable gene delivery system that has demonstrated remarkable safety and single-agent efficacy in clinical trials internationally. Rexin-G is currently in clinical trials for pancreatic cancer in the U.S. ƒƒ‚ƒš‚" where it has achieved FDA orphan drug status ƒƒ‚ƒš‚" and has accelerated approval in the Philippines for the treatment of all solid tumors that are resistant to standard chemotherapy. The company's international clinical outreach with Rexin-G has enabled us to expedite further demonstrations that Rexin-G is highly active in a broad spectrum of chemo-resistant tumor types with efficacy and excellent safety profiles. The company are a biopharmaceutical company focused on expanding the therapeutic utility and commercialization of the company's pathotropic approach to disease treatment through internal development and commercialization of the company's oncology products and cancer vaccines, and through strategic partnerships in additional areas of oncology, immunology, cardiovascular, ocular, and wound healing applications, precision targeted diagnostics, and stem cell technologies.
ASC is a privately held biotechnology company dedicated to the development and commercialization of enabling technologies to enhance and expand the therapeutic potential of stem cell therapies. The key technology platforms (ASC-101 and ASC-201) are designed to improve the homing and engraftment of stem cells to target organs and increase their therapeutic potential for cancer patients. Additionally, these platforms have the potential to enhance stem cell treatment of inflammation from chemotherapy/radiation, solid tumors, autoimmune diseases, and ischemic diseases including myocardial infarction and stroke. ASC has strategic partnerships with medical research institutions including the University of Texas M.D. Anderson Cancer Center, the Oklahoma Medical Research Foundation, University of California, the Burnham Institute, Indiana University, Rush Presbyterian and VidaCord Technologia Biomedica.
Altair Therapeutics is a biotechnology company focused on the discovery, development and commercialization of antisense drugs for respiratory conditions.
Arbor Fuel is a technology company formed to utilize the power of biotechnology for the generation of alternative fuels. Advancements in the understanding of microbiological processing of cellulose based plant material have opened the opportunity to generate cell lines and biological processes to covert cellulosic material into fuel. The company believes that by coupling genomic approaches with the cell culturing technologies utilized in biotherapeutic drug development they can make cell lines for cost effective generation of fuel from plant material a reality.
Chroma Therapeutics is a biotechnology company founded to exploit the potential of chromatin biology for cancer drug discovery. Chroma is focused on the identification of anti-cancer agents that combine the efficacy of cytotoxics with the tumour cell selectivity of modern targeted therapeutics. Based in Oxford, UK, Chroma is developing a pipeline of anti-cancer drugs.
Trellis Bioscience provides health care products and services. The Company develops treatments for infectious diseases and oncology indications such as therapeutic antibody treatments.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.